➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Johnson and Johnson
AstraZeneca
Boehringer Ingelheim
Medtronic

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

TRANXENE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Tranxene patents expire, and when can generic versions of Tranxene launch?

Tranxene is a drug marketed by Recordati Rare and is included in one NDA.

The generic ingredient in TRANXENE is clorazepate dipotassium. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the clorazepate dipotassium profile page.

Drug patent expirations by year for TRANXENE
Drug Prices for TRANXENE

See drug prices for TRANXENE

Recent Clinical Trials for TRANXENE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Polish Lymphoma Research GroupPhase 4
Ranbaxy Laboratories LimitedN/A

See all TRANXENE clinical trials

Pharmacology for TRANXENE
Drug ClassBenzodiazepine

US Patents and Regulatory Information for TRANXENE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Recordati Rare TRANXENE clorazepate dipotassium CAPSULE;ORAL 017105-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Recordati Rare TRANXENE SD clorazepate dipotassium TABLET;ORAL 017105-005 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Recordati Rare TRANXENE clorazepate dipotassium TABLET;ORAL 017105-006 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Recordati Rare TRANXENE SD clorazepate dipotassium TABLET;ORAL 017105-004 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Recordati Rare TRANXENE clorazepate dipotassium CAPSULE;ORAL 017105-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Recordati Rare TRANXENE clorazepate dipotassium CAPSULE;ORAL 017105-003 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Recordati Rare TRANXENE clorazepate dipotassium TABLET;ORAL 017105-008 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TRANXENE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Recordati Rare TRANXENE clorazepate dipotassium TABLET;ORAL 017105-008 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Recordati Rare TRANXENE clorazepate dipotassium CAPSULE;ORAL 017105-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Recordati Rare TRANXENE clorazepate dipotassium CAPSULE;ORAL 017105-003 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Recordati Rare TRANXENE clorazepate dipotassium CAPSULE;ORAL 017105-002 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Recordati Rare TRANXENE clorazepate dipotassium TABLET;ORAL 017105-006 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Recordati Rare TRANXENE clorazepate dipotassium TABLET;ORAL 017105-007 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKesson
Johnson and Johnson
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.